# CABOMETYX® (cabozantinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cabozantinib

> The FDA approved CABOMETYX® (cabozantinib), sponsored by EXELIXIS, INC. (EXEL), on May 13, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CABOMETYX® (cabozantinib) |
| Codes | XL184 |
| Sponsor | EXELIXIS, INC. (EXEL) https://sec-api.dev/companies/exel/catalysts |
| Indications | previously treated advanced net, measurable, extra-pelvic metastatic castration-resistant prostate cancer, with previously treated advanced net, measurable, extra-pelvic mcrpc, [Cancer](https://sec-api.dev/indications/cancer) |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### Aug 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: measurable, extra-pelvic metastatic castration-resistant prostate cancer.
- First seen 2025-02-11, last confirmed 2026-02-10.
- SEC Form 10-Q (accession 0000939767-25-000113): "In August 2023, we announced positive top-line results from CONTACT-02, a phase 3 pivotal trial sponsored by us and co-funded by Roche, evaluating the combination of cabozantinib and Roche's ICI, atezolizumab, versus a second novel hormonal therapy (NHT) in patients with measurable, extra-pelvic metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with one prior NHT." https://www.sec.gov/Archives/edgar/data/939767/000093976725000113/exel-20250704.htm
- SEC Form 10-Q (accession 0000939767-25-000075): "In August 2023, we announced positive top-line results from CONTACT-02, a phase 3 pivotal trial sponsored by us and co-funded by Roche, evaluating the combination of cabozantinib and Roche's ICI, atezolizumab, versus a second novel hormonal therapy (NHT) in patients with measurable, extra-pelvic metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with one prior NHT." https://www.sec.gov/Archives/edgar/data/939767/000093976725000075/exel-20250404.htm
- SEC Form 10-K (accession 0000939767-25-000019): "In August 2023, we announced positive top-line results from CONTACT-02, a phase 3 pivotal trial sponsored by us and co-funded by Roche, evaluating the combination of cabozantinib and Roche's ICI, atezolizumab, versus a second NHT in patients with measurable, extra-pelvic mCRPC who have progressed after treatment with one prior NHT." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- SEC Form 10-K (accession 0000939767-26-000021): "In August 2023, we announced positive top-line results from CONTACT-02." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm
- SEC Form 10-K (accession 0000939767-25-000019): "In August 2023, we announced positive top-line results that the trial met one of two primary endpoints, demonstrating a statistically significant improvement in PFS (HR: 0.65; 95% CI: 0.50-0.84; p=0.0007) in the predefined PFS intent-to-treat population (i.e., the first 400 randomized patients), and these data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in January 2024." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm

### Aug 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-11, last confirmed 2025-02-11.
- SEC Form 10-K (accession 0000939767-25-000019): "In August 2024, we announced that the FDA had accepted our sNDA seeking approval for cabozantinib to" https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- SEC Form 10-K (accession 0000939767-25-000019): "In August 2024, we announced that the FDA had accepted our sNDA seeking approval for cabozantinib to treat adult patients with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pNET or epNET, granted standard review in the U.S., and assigned a PDUFA target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- SEC Form 10-K (accession 0000939767-25-000019): "•In August 2024, we announced that the FDA had accepted our sNDA for CABOMETYX as a treatment for adult patients with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pNET and epNET, granted standard review and assigned a PDUFA target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm

### Mar 2025: FDA advisory committee meeting

- Status: scheduled. Date confidence: month.
- First seen 2025-02-11, last confirmed 2025-02-11.
- SEC Form 10-K (accession 0000939767-25-000019): "In November 2024, we announced that our sNDA would be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025; however, in January 2025, we announced that the FDA had notified us that our sNDA would no longer be the subject of discussion at an ODAC." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- SEC Form 10-K (accession 0000939767-25-000019): "In November 2024, we announced that our sNDA would be discussed at an ODAC meeting in March 2025; however, in January 2025, we announced that the FDA had notified us that our sNDA would no longer be the subject of discussion at an ODAC." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm

### Mar 2025: FDA approval

- Status: completed, approved. Date confidence: month. Stage: 3. Indication: previously treated advanced NET.
- First seen 2025-05-13, last confirmed 2026-02-10.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000019): "In March 2025, the U.S. FDA approved CABOMETYX for two new NET indications, advanced pancreatic and extra-pancreatic NET (pNET and epNET), based on results from the CABINET study." https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm
- SEC Form 10-K (accession 0000939767-26-000021): "In March 2025, we announced that the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET and epNET." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm
- SEC Form 10-K (accession 0000939767-26-000021): "•In March 2025, we announced FDA Approval of CABOMETYX for patients with previously treated advanced NET." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000127): "In March 2025, the U.S. Food and Drug Administration (FDA) approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET), based on results from the CABINET study." https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel20250930exhibit991.htm
- SEC Form 10-Q (accession 0000939767-25-000075): "•In March 2025, we announced FDA Approval of CABOMETYX for patients with previously treated advanced NET." https://www.sec.gov/Archives/edgar/data/939767/000093976725000075/exel-20250404.htm
- SEC Form 10-K (accession 0000939767-26-000021): "Clinical trials conducted with support from these external partners have enabled further expansion of the cabozantinib development program and cabozantinib franchise with less burden on our internal development resources, most recently reflected by the March 2025 FDA approval of CABOMETYX for patients with previously treated advanced NET, which was based on results from the Alliance-led CABINET phase 3 pivotal study." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm

### Q2 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-05-06, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001724521-25-000061): "•Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025" https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/a2025q18kexhibit991.htm

### April 3, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: with previously treated advanced NET.
- First seen 2025-01-13, last confirmed 2025-02-11.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000017): "In January 2025, Exelixis announced its key priorities and anticipated milestones for 2025, including: the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following completion of the FDA's review of Exelixis' sNDA, which has a PDUFA action date of April 3, 2025; expansion of zanzalintinib's pivotal development program with six ongoing or planned pivotal trials, including two pivotal RCC studies with Merck and additional" https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000004): "Exelixis is preparing for the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following the FDA's acceptance of its sNDA and assignment of a PDUFA target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm
- SEC Form 10-K (accession 0000939767-25-000019): "In August 2024, we announced that the FDA had accepted our sNDA seeking approval for cabozantinib to treat adult patients with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pNET or epNET, granted standard review in the U.S., and assigned a PDUFA target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- SEC Form 10-K (accession 0000939767-25-000019): "•In August 2024, we announced that the FDA had accepted our sNDA for CABOMETYX as a treatment for adult patients with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pNET and epNET, granted standard review and assigned a PDUFA target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000017): "We're launch-ready for this important indication ahead of an April 3, 2025 PDUFA target action date for our U.S. regulatory filing."" https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000017): "The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' supplemental New Drug Application (sNDA) for this proposed indication, with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000004): "The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' supplemental New Drug Application (sNDA) for this proposed indication, with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm
- SEC Form 10-K (accession 0000939767-25-000019): "Table of Contents treat adult patients with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pNET or epNET, granted standard review in the U.S., and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000074): "In March, Exelixis announced that the U.S. FDA approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET)." https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel20250331exhibit991.htm

### May 13, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-13, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000074): "In March, Exelixis announced that the U.S. FDA approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET)." https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel20250331exhibit991.htm

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07620574 (Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-05-31 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT07620574

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07620574 (Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-05-31 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT07620574

## Same indication

- [9-ing-41](https://sec-api.dev/pdufa/9-ing-41) (ACTU)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cabozantinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CABOMETYX® (cabozantinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cabozantinib

```bibtex
@misc{secapidev_pdufa_cabozantinib_20261116,
  title        = {CABOMETYX® (cabozantinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cabozantinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cabozantinib_20261116","title":"CABOMETYX® (cabozantinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cabozantinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
